参考文献/References:
[1] RossR.Atherosclerosis—An Inflammatory Disease[J].New Engl J Med,1999,340(2):115-126.
[2]Duewell P, Kono?H, Rayner KJ, et al.NLRP3 inflammasomes arerequired for atherogenesis and activated by cholesterol crystals[J]. Nature,2010,464(7293):1357-1361.
[3]Rock KL, Latz E, Ontiveros F,et al.The sterile inflammatory response[J].Annu Rev Immunol,2010,28:321-342.
[4]Martinon F,Burns K,Tschopp J. The inflammasome:a molecular platform triggering activation of inflammatory caspases and processing of proIL- beta[J]. Mol Cell,2002,10(2):417-426.
[5]Bauernfeind FG,Horvath G,Stutz A,et al.Cutting edge:NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression[J]. J Immunol,2009,183(2):787-791.
[6]Libby P. History of discovery: in?ammation in?atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2012,32(9):2045-2051.
[7]Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity[J]. Immunol Rev,2018,281(1):8-27.
[8]Abais JM, Xia M, Zhang Y,et al. Redox regulation of NLRP3 inflammasomes：ROS as trigger or effector?[J].Antioxid Redox Signal,2015,22(13):1111-1129.
[9]Dubyak GR.P2X7 receptor regulation of non- classical secretion from immune effector cells[J]. Cellular Microbiol,2012,14(11):1697-1706.
[10]Orlowski?GM,Colbert?JD,SharmaS,et al.Multiple?cathepsins?promote?pro-IL-1β?synthesis and NLRP3-mediated IL-1β?activation[J]. J Immunology, 2015,195(4):1685-1697.
[11]Zhou R,Tardivel A,Thorens B,et al.Thioredoxin-interacting protein links oxidative stress to inflammasome activation[J].Nat Immunol,2010,11(2):136-140.
[12]Hoseini Z,Sepahvand F,Rashidi B,et al. NLRP3 inflammasome:its regulation and involvement in atherosclerosis[J]. J Cell Physiol,2018,233(3):2116-2132.
[13]Galea J, Armstrong J, Gadsdon P, et al. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease[J].Arterioscler Thromb Vasc Biol,1996,16(8):1000-1006..
[14]Kirii H,Niwa T,Yamada Y,et al.Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice[J].Arterioscler Thromb Vasc Biol, 2003,23(4):656-660.
[15]Bhaskar V,Yin J, Mirza AM, et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice[J].Atherosclerosis, 2011,216(2):313-320.
[16]Zheng F,Xing S,Gong Z,et al. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis[J]. Heart Lung Circ,2013,22(9):746-750.
[17]Bando S, Fukuda D, Soeki T, et al. Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis[J]. Atherosclerosis,2015,242(2):407-414.
[18]Paramel Varghese G, Folkersen L, Strawbridge RJ, et al. NLRP3 inflammasome expression and activation in human atherosclerosis[J]. J Am Heart Assoc,2016,5(5):e003031.
[19]Shi?X,Xie WL,Kong WW, et al.Expression of the NLRP3 inflammasome in carotid atherosclerosis[J]. J Stroke Cerebrovasc Dis,2015,24(11):2455-2466.
[20]Ridker PM, Everett BM, Thuren T, et al. Anti-in?ammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[21]Libby P. Interleukin-1 beta as a target for?atherosclerosis therapy: biological basis of?CANTOS and beyond[J]. JACC, 2017,70(18):?2278-2289.
[22]Ridker PM,Everett BM,Pradhan A,et al. Low-dose methotrexate for the prevention of atherosclerotic events[J]. N Engl J Med,2019,380(8):752-762.
[23]Chan ES, Cronstein BN. Methotrexate—how does it really work? [J].Nat Rev Rheumatol,2010;6(3):175-178.
[24]Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection[J]. Circ Res,2016,118(1):145- 156.
[25]Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction[J]. Nat Rev Cardiol,2018,15(4):203-214.
[26]van der Heijden T,Kritikou E,Venema W,et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein edeficient mice-brief report[J].Arterioscler Thromb Vasc Biol,2017,37(8):1457-1461.
[27]van Hout GP,Bosch L,Ellenbroek GH,et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction[J]. Eur Heart J,2017,38(11):828- 836.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(6):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(6):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[3]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[4]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(6):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(6):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[8]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[9]宋志平 杨永健.GPR 35在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
SONG Zhiping,YANG Yongjian.The Current Progress of GPR 35 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(6):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
[11]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[12]张颖怡 刘金波 刘欢 赵娜 赵红薇 王宏宇.全身动脉粥样硬化斑块与脑梗死的关系：北京血管病变评价研究结果[J].心血管病学进展,2021,(3):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]
ZHANG YingyiLIU J inboLIU HuanZHAO NaZHAO HongweiWANG Hongyu.The Relationship Between Systematic Atherosclerotic Plaques and Cerebral Infarction:Results from Beijing Vascular Disease Evaluation Study[J].Advances in Cardiovascular Diseases,2021,(6):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]
[13]李佳珊 关秀茹.ABCA1：调控胆固醇逆向转运与炎症激活之间关系的研究新进展[J].心血管病学进展,2021,(7):649.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.018]
LI Jiashan,GUAN Xiuru.ABCA1: New Progress in Regulating the Relationship Between Cholesterol Reverse Transport and Inflammation Activation[J].Advances in Cardiovascular Diseases,2021,(6):649.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.018]
[14]原达 朱国斌.血小板P选择素及CD40/CD40L在动脉粥样硬化中的研究进展[J].心血管病学进展,2021,(10):928.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.016]
YUAN Da,ZHU Guobin.Research Progress of Platelet-Related P-Selectin and?D40L Pro-Inflammatory Effects in Atherosclerosis[J].Advances in Cardiovascular Diseases,2021,(6):928.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.016]
[15]肖明瑛 苏冠华.PCSK9抑制剂多效性研究进展[J].心血管病学进展,2022,(2):124.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.008]
XIAO MingyingSU Guanhua.Pleiotropic Effects of PCSK9 Inhibitors[J].Advances in Cardiovascular Diseases,2022,(6):124.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.008]
[16]王朝阳 赵丽娜 田师鹏 陈淑霞 谷剑.炎症治疗在动脉粥样硬化中的研究进展[J].心血管病学进展,2023,(6):519.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.009]
WANG Zhaoyang,ZHAO Lina,TIAN Shipeng,et al.Advances in the Treatment of Inflammation in Atherosclerosis[J].Advances in Cardiovascular Diseases,2023,(6):519.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.009]